Study aims to distinguish stable vs worsening early myeloma
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This study looks at two different “precursor” conditions that can happen before multiple myeloma: MGUS and smoldering myeloma (SMM). Researchers want to better tell which cases are more likely to progress, using blood/urine tests and sometimes bone marrow tissue.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are an adult (age 18 or older).
- You have a confirmed diagnosis of MGUS or smoldering myeloma (SMM).
- Your diagnosis must be confirmed by specific lab tests (blood/urine protein tests, light-chain tests) and/or a bone marrow biopsy study.
- You can perform normal daily activities with some limits (ECOG 0 to 3).
- You are able to understand and sign consent for the study.
- You must not have had previous treatment for multiple myeloma.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This is an observational study that follows people with early blood findings that can be linked to multiple myeloma, to understand what happens over time. It does not test a new drug for most people; instead, it tracks health, lab results, and imaging to learn who may develop myeloma.
This study follows people with early, “precursor” blood conditions to learn what changes in their blood or bone marrow signal progression. It may help doctors better predict outcomes and understand why some people develop symptom-causing cancer.
This trial watches people with a high-risk form of smoldering myeloma (an early, inactive stage of bone marrow cancer) to learn more about how it changes. It may help doctors know who needs treatment later.
This study uses a blood test to find early signs of myeloma in people at higher risk, such as those with a family history or African ancestry. It aims to predict who might develop myeloma before symptoms appear.
This study looks at how patients feel day to day (quality of life) while they are monitored or treated for MGUS or smoldering multiple myeloma. It is designed for people who do NOT yet have “myeloma defining events” or amyloidosis, because the goal is to understand well-being in earlier disease stages.
This study is for people who are newly diagnosed with either a very early blood condition (MGUS or smoldering myeloma) or AL amyloidosis, and who have not yet had treatment. It aims to help doctors better diagnose and manage these conditions in Italy.
Hear when a new Multiple myeloma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.